What Ketamine's Side Effect Data Means for You

Clinicians Are Pushing for Smarter, Faster Depression Care — Here's What That Means for Ketamine Patients

A new clinical analysis published in Psychiatric Times in April 2026 is putting hard numbers behind something many ketamine patients already feel intuitively: when treatment isn't working or is causing intolerable side effects, waiting too long to adjust course costs people their wellbeing. The piece examines the side effect profiles and discontinuation rates of NMDA receptor antagonists — a class that includes both IV ketamine and intranasal esketamine (Spravato) — in patients with treatment-resistant depression (TRD), and it calls on clinicians to move faster, track outcomes more rigorously, and optimize dosing with greater urgency.

For the growing number of Americans pursuing ketamine treatment through online and telehealth platforms, this guidance carries real, practical weight. Understanding what the data says — and what questions it should prompt you to ask your provider — can meaningfully affect your outcomes.

What the Research Found

The Psychiatric Times analysis synthesizes current evidence on how patients tolerate NMDA receptor antagonists over time. The findings highlight several consistent themes: dissociative symptoms, nausea, dizziness, and elevated blood pressure are the most commonly reported short-term side effects for both IV ketamine and esketamine. These effects are typically transient — peaking during or shortly after infusion and resolving within hours — but for some patients, they are significant enough to prompt discontinuation.

Discontinuation rates, the analysis notes, vary considerably depending on the treatment setting, monitoring protocols, and how quickly clinicians respond to patient-reported symptoms. Programs that actively track side effects between sessions and adjust dosing accordingly show meaningfully lower dropout rates than those with minimal follow-up contact. The clinical takeaway, as framed by the authors, is unambiguous: waiting passively for a patient to self-report intolerable effects is a losing strategy. Proactive, structured symptom monitoring — including standardized tools like the PHQ-9 for depression severity — produces better adherence and faster paths to remission.

The analysis also flags that patients who don't see meaningful improvement within the first three to four treatment sessions may benefit from a dosing adjustment or a switch to a different agent sooner rather than later. In other words, the old model of "give it more time" is being replaced by a data-driven, response-adaptive approach.

Why This Matters for Online Ketamine Patients Specifically

Telehealth ketamine care has expanded access dramatically over the past several years, allowing patients in states that previously had no local infusion options to connect with board-certified providers and receive treatment — often for a fraction of the cost of in-person clinic visits. But expanded access has also introduced variation in care quality, and the clinical standards described in this analysis give patients a useful benchmark for evaluating whether their provider is meeting a reasonable bar.

Here's what this research implies for anyone currently in or considering an online ketamine program:

• Side effect check-ins should be built into your program, not optional. Reputable telehealth ketamine providers don't just schedule your next session — they follow up between sessions to assess how you're tolerating treatment. If your provider isn't asking about dissociation, nausea, cardiovascular symptoms, or mood changes in the days following each session, that's a gap worth raising directly.
• PHQ-9 tracking is a signal of clinical rigor. The PHQ-9 is a validated, nine-question depression screening tool that takes under two minutes to complete. Programs that administer it regularly — ideally before each session — can detect whether you're actually responding to treatment, plateauing, or declining. Ask your provider how they measure your progress over time. "We check in with you" is not the same as a structured, validated outcome measure.
• Dose optimization should be an active conversation, not a fixed protocol. Not every patient responds to the same ketamine dose, and the evidence increasingly supports adjusting based on individual response rather than adhering rigidly to a one-size-fits-all schedule. If you've completed a full initial series without meaningful relief, your provider should be discussing what's next — not simply extending the same protocol indefinitely.
• Discontinuation isn't failure — but unmanaged discontinuation is a risk. Some patients do discontinue ketamine treatment, and the reasons range from insufficient efficacy to intolerable side effects to cost. What the research underscores is that abrupt, unplanned discontinuation — especially without a transition plan — leaves patients without adequate support. A good telehealth provider will have a clear protocol for what happens if ketamine isn't the right fit, including referrals, medication management coordination, and follow-up care.

The Broader Shift in Clinical Culture

What's notable about this analysis is not just the data itself, but the posture it reflects among clinicians treating TRD. There's a growing consensus in psychiatry that the traditional "wait and see" approach to antidepressant treatment — whether that's SSRIs, SNRIs, or ketamine — causes unnecessary suffering. Every month a patient spends in inadequate treatment is a month of lost function, strained relationships, and compounding risk.

The push toward faster, more responsive care is especially relevant in the ketamine space, where the treatment window can feel more compressed. Ketamine's antidepressant effects tend to emerge quickly relative to oral medications, but they also require maintenance strategies to sustain. Patients and providers who track outcomes systematically are better positioned to make smart decisions about booster sessions, adjunctive therapies, and long-term care architecture.

For patients choosing between telehealth providers, this research gives you a practical filter: look for programs that treat outcome tracking as a clinical obligation, not an afterthought. The field is moving in a clear direction, and providers who haven't kept pace represent a meaningful quality gap.

You can read the full analysis at Psychiatric Times.